13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001009258
Total reported value
$9.6B
$9.6B
152 檔
26.9%
According to the latest 13F quarterly dataset, Deerfield Management Company, L.p. managed an equity portfolio of $9.6B at the end of Q3 2025, spanning 152 distinct U.S. exchange-listed positions.
In Q3 2025, Deerfield Management Company, L.p. displayed an active expansion posture, initiating 84 new positions and adding to 25 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NUVL | Nuvalent Inc-a | Stock-Other | 23.75% | +1.37% | — | |
| 2 | CNC | Centene CORP | Stock-Healthcare | 4.93% | +0.99% | +183.99% | |
| 3 | ✓ | Merus N V | Stock-Other | 4.38% | — | -9.98% | |
| 4 | VTRS | Viatris Inc | Stock-Healthcare | 3.64% | +0.13% | +0.31% | |
| 5 | UTHR | United Therapeutics CORP | Stock-Healthcare | 2.73% | -0.62% | -21.20% | |
| 6 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.60% | +2.03% | +7.87% | |
| 7 | INDV | Indivior Pharmaceuticals, Inc. | Stock-Other | 2.57% | — | -33.88% | |
| 8 | MIRM 4 05-01-29Bond | Mirum Pharmaceuticals | Bond | 2.57% | -2.47% | EXIT | |
| 9 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.54% | -0.95% | EXIT | |
| 10 | COGT | Cogent Biosciences Inc | Stock-Other | 1.98% | -2.09% | +242.89% | |
| 11 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.98% | -0.11% | — | |
| 12 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.85% | -0.10% | -16.60% | |
| 13 | VERA | Vera Therapeutics Inc | Stock-Other | 1.62% | -0.02% | +8.75% | |
| 14 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 1.61% | — | — | |
| 15 | AHCO | Adapthealth CORP | Stock-Other | 1.57% | -0.36% | +15.88% | |
| 16 | LRMR | Larimar Therapeutics Inc | Stock-Other | 1.51% | -0.76% | +44.16% | |
| 17 | BKD | Brookdale Senior Living Inc | Stock-Other | 1.51% | +0.07% | -24.22% | |
| 18 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 1.50% | -1.15% | EXIT | |
| 19 | LEGN | Legend Biotech Corp-adr | Stock-Other | 1.47% | +0.81% | — | |
| 20 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.41% | -0.12% | +159.36% | |
| 21 | TNDM 1.5 03-15-29 2024Bond | Tandem Diabetes Care Inc | Bond | 1.33% | — | +150.00% | |
| 22 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.32% | — | +20.09% | |
| 23 | PFE | Pfizer Inc | Stock-Healthcare | 1.29% | -0.25% | -23.28% | |
| 24 | IONS 1.75 06-15-28Bond | Ionis Pharmaceuticals In | Bond | 1.26% | -0.10% | — | |
| 25 | CERT | Certara Inc | Stock-Other | 1.26% | -0.02% | +71.66% | |
| 26 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 1.19% | -1.04% | +648.35% | |
| 27 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 1.15% | -0.08% | -22.84% | |
| 28 | INSM | Insmed Inc | Stock-Healthcare | 1.04% | — | -32.78% | |
| 29 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 0.97% | -0.05% | — | |
| 30 | NEO 0.25 01-15-28Bond | Neogenomics Inc | Bond | 0.96% | -0.66% | — | |
| 31 | PHVS | Pharvaris N.V. | Stock-Other | 0.93% | +0.18% | +21.07% | |
| 32 | IRON | Disc Medicine Inc | Stock-Other | 0.93% | — | — | |
| 33 | IDYA | Ideaya Biosciences Inc | Stock-Other | 0.89% | +0.46% | -45.01% | |
| 34 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 0.86% | -0.13% | — | |
| 35 | NVST | Envista Holdings CORP | Stock-Healthcare | 0.71% | -0.05% | +3.53% | |
| 36 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.68% | -0.30% | +22.41% | |
| 37 | CRMD | Cormedix Inc | Stock-Other | 0.59% | — | — | |
| 38 | EHABUSD | Enhabit Inc | Stock-Other | 0.58% | -0.79% | EXIT | |
| 39 | EMBC | Embecta CORP | Stock-Healthcare | 0.56% | -0.17% | -4.70% | |
| 40 | LIVN 2.5 03-15-29Bond | Livanova PLC | Bond | 0.56% | +0.01% | +37.12% | |
| 41 | CELC | Celcuity Inc | Stock-Other | 0.55% | -0.73% | — | |
| 42 | CNMD | Conmed CORP | Stock-Other | 0.55% | — | +8.56% | |
| 43 | ZBIO | Zenas Biopharma Inc | Stock-Other | 0.53% | — | — | |
| 44 | NEO | Neogenomics Inc | Stock-Healthcare | 0.52% | — | +107.05% | |
| 45 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.52% | +0.02% | — | |
| 46 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.51% | -0.94% | EXIT | |
| 47 | KYMR | Kymera Therapeutics Inc | Stock-Other | 0.49% | -0.55% | EXIT | |
| 48 | CDNA | Caredx Inc | Stock-Other | 0.49% | +0.14% | — | |
| 49 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.47% | -0.06% | -53.15% | |
| 50 | ACHC | Acadia Healthcare Co Inc | Stock-Other | 0.45% | +0.14% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ✓ | Merus N V | +1.7% | -9.98% | Trim |
| 2 | CNC | Centene CORP | +1.7% | +183.99% | Add |
| 3 | COGT | Cogent Biosciences Inc | +1.7% | +242.89% | Add |
| 4 | VERA | Vera Therapeutics Inc | +1.1% | +8.75% | Add |
| 5 | UTHR | United Therapeutics CORP | +1.1% | -21.20% | Add |
| 6 | CERT | Certara Inc | +0.9% | +71.66% | Add |
| 7 | BCRX | Biocryst Pharmaceuticals Inc | +0.6% | +159.36% | Add |
| 8 | LRMR | Larimar Therapeutics Inc | +0.6% | +44.16% | Add |
| 9 | INDV | Indivior Pharmaceuticals, Inc. | +0.6% | -33.88% | Trim |
| 10 | INSM | Insmed Inc | +0.4% | -32.78% | Add |
| 11 | MIRM 4 05-01-29Bond | Mirum Pharmaceuticals | +0.3% | — | Unchanged |
| 12 | LEGN | Legend Biotech Corp-adr | +0.3% | — | Add |
| 13 | PHVS | Pharvaris N.V. | +0.3% | +21.07% | Add |
| 14 | ZBIO | Zenas Biopharma Inc | +0.3% | — | Unchanged |
| 15 | SION | Sionna Therapeutics Inc | +0.3% | — | Add |
| 16 | RVMD | Revolution Medicines Inc | +0.3% | +7.87% | Add |
| 17 | PRAX | Praxis Precision Medicines I | +0.2% | +22.41% | Add |
| 18 | NAMS | NewAmsterdam Pharma Company N.V. | +0.2% | -16.60% | Add |
| 19 | KYMR | Kymera Therapeutics Inc | +0.2% | -12.36% | Trim |
| 20 | IRON | Disc Medicine Inc | +0.2% | — | Add |
| 21 | BBNX | Beta Bionics Inc | +0.1% | — | Add |
| 22 | TOI | Oncology Institute Inc/the | +0.1% | — | Unchanged |
| 23 | DAWNGBX | Day One Biopharmaceuticals I | +0.1% | +26.38% | Add |
| 24 | GPCR | Structure Therapeutics Inc | 0% | — | Unchanged |
| 25 | NVST | Envista Holdings CORP | 0% | +3.53% | Add |
| 26 | SYRE | Spyre Therapeutics Inc | 0% | — | Add |
| 27 | ALEC | Alector Inc | 0% | — | Unchanged |
| 28 | FHTX | Foghorn Therapeutics Inc | 0% | — | Unchanged |
| 29 | CALC | Calcimedica Inc | 0% | — | Unchanged |
| 30 | ANNX | Annexon Inc | 0% | — | Unchanged |
| 31 | ✓ | Newamsterdam Pharma Company | — | — | Unchanged |
| 32 | TOIIW | Oncology Institute Inc Cw-22 | — | — | Unchanged |
| 33 | CYH | Community Health Systems Inc | — | -41.26% | Add |
| 34 | QSIAW | Quantum-si Inc -cw27 | — | — | Unchanged |
| 35 | SVRA | Savara Inc | 0% | — | Unchanged |
| 36 | TWST | Twist Bioscience CORP | 0% | — | Unchanged |
| 37 | ✓ | 0% | — | Unchanged | |
| 38 | IMCR 2.5 02-01-30Bond | Immunocore Holdings | -0.1% | — | Unchanged |
| 39 | PHR | Phreesia Inc | -0.1% | +10.07% | Add |
| 40 | BIO | Bio-rad Laboratories-a | -0.1% | — | Unchanged |
| 41 | EMBC | Embecta CORP | -0.1% | -4.70% | Trim |
| 42 | CPRX | Catalyst Pharmaceuticals Inc | -0.1% | +72.77% | Add |
| 43 | DCGO | Docgo Inc | -0.2% | -6.45% | Trim |
| 44 | IDYA | Ideaya Biosciences Inc | -0.2% | -45.01% | Trim |
| 45 | IART | Integra Lifesciences Holding | -0.2% | — | Unchanged |
| 46 | CNMD | Conmed CORP | -0.2% | +8.56% | Add |
| 47 | TXG | 10x Genomics Inc-class A | -0.2% | +2211.19% | Trim |
| 48 | EHABUSD | Enhabit Inc | -0.3% | -0.67% | Trim |
| 49 | LNTH 2.625 12-15-27Bond | Lantheus Holdings Inc | -0.3% | — | Unchanged |
| 50 | ALNY | Alnylam Pharmaceuticals Inc | -0.3% | -53.15% | Trim |
According to official SEC Form 13F filings, Deerfield Management Company, L.p. reported a total U.S. public equity portfolio value of $9.6B across 152 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NUVL, CNC, MERUS N V) accounted for 26.9% of total reported equity market value during Q3 2025.
Top New Position Initiated
IONS
市值: $129.5M
Top Position Liquidated / Trimmed
IART 0.5 08-15-25
前期市值: $171.0M
During Q3 2025, Deerfield Management Company, L.p.'s top holdings by market value included NUVL (23.8%)、CNC (4.9%)、MERUS N V (4.4%). The largest single position, NUVL, represented 23.8% of total portfolio value.
In Q3 2025, Deerfield Management Company, L.p. made 181 total portfolio adjustments, initiating 84 new buys, adding to 25 positions, trimming 17 holdings, and fully liquidating 55 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.